WebIntensive treatment (such as a stem cell transplant) is often used when possible, as there is a high risk of recurrence after treatment. Prognostic factors for ALL As leukemia … WebFeb 17, 2024 · As patients advanced to later lines, the use of triplet therapy decreased. Patients received similar treatments in each line of therapy with different cytogenetic risk. In the first-line setting, 85% of high-risk patients, 79% of t(11;14)+ patients, and 78% of standard-risk patients received a proteasome inhibitor (PI)-containing regimen.
Phase-2 trial of an intensified conditioning regimen for ... - PubMed
WebAug 11, 2024 · Translocation t (4;14), t (14;16) and t (14;20) have been associated with poor prognosis, and their presence identifies high-risk (HR) disease. On the other hand, … WebFeb 1, 2024 · But cytogenetic high risk is determined on the bone marrow biopsy. And when we do a bone marrow, the first thing [examined] is how much myeloma—is there a little or a lot? But then we also send ... highstakesweeps download
Acute Lymphocytic Leukemia (ALL) Subtypes and Prognostic …
WebIntensive treatment (such as a stem cell transplant) is often used when possible, as there is a high risk of recurrence after treatment. Prognostic factors for ALL As leukemia treatment has improved over the years, research has focused on why some people have a better chance for cure than others. WebSep 15, 2024 · TARGETED ONCOLOGY: What benefits were observed with the isatuximab triplet in the high-risk cytogenetic population? Harrison: In the high-risk cytogenetic population, we saw a significant increase in response rate up to about 50% compared with 20%. The majority of that benefit was an increase in very good partial response (VGPR) … WebNov 13, 2024 · The 1 year OS for those with high risk cytogenetics and IHC was 29% [95% CI: 4% to 61%] versus those without at 76% [52% to 89%]. Consistent with prior studies, pts … small sherry glasses